BioNTech (BNTX) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic achievements and financial position

• Delivered five billion vaccine doses globally, launched a variant-adapted COVID-19 vaccine, and maintained over 50% global market share in key regions.

• Executed key partnerships, notably with Bristol Myers Squibb, and acquired Biotheus and CureVac.

• Ended 2025 with a cash balance of €17.2 billion and over $17 billion in cash and equivalents.

• Increased 2025 revenue guidance to €2.6–2.8 billion, with high-margin COVID-19 vaccine business funding oncology innovation.

• Revenues from COVID vaccines are being used to finance oncology programs, with disciplined resource allocation.

Oncology pipeline and development strategy

• Over 25 ongoing phase 2 and 3 oncology trials, with 15–17 late-stage/pivotal readouts expected in 2026–2027.

• Key assets include Prometimic/Pumitamig (PD-L1 x VEGF bispecific), Gotistobart (CTLA-4 Treg depleter), and BNT324/DB-1311 (B7-H3 ADC).

• Pursuing synergy-driven approaches across immunomodulators, ADCs, and mRNA cancer immunotherapies.

• Tumor-centric development is prioritized, focusing on high-prevalence solid tumors and unmet medical needs.

• Building a multi-product oncology company by 2030, targeting broad late-stage acceleration and combination therapy momentum.

Clinical data and upcoming milestones

• Prometimic/Pumitamig shows efficacy across 18 tumor types, with over 1,600 patients studied and 8 pivotal studies ongoing.

• Gotistobart demonstrated a 54% reduction in risk of death in CPI-treated squamous NSCLC; pivotal phase 3 data expected in 2026.

• BNT324/DB-1311 demonstrates strong antitumor activity and favorable safety in mCRPC, with phase 3 trial planned for 2026.

• Over 15 data readouts anticipated in 2026, including pivotal and early-stage combination trials.

• mRNA immunotherapies (Autogene Cevumeran, FixVac) induce broad T cell responses and show survival benefit in early trials.